Skip to main content
HLB Therapeutics Co.,Ltd. logo

HLB Therapeutics Co.,Ltd. — Investor Relations & Filings

Ticker · 115450 ISIN · KR7115450009 KO Manufacturing
Open in API
Filings indexed 444 across all filing types
Latest filing 2021-02-10 Major Shareholding Noti…
Country KR South Korea
Listing KO 115450

About HLB Therapeutics Co.,Ltd.

https://hlbtherapeutics.co.kr/en/

HLB Therapeutics Co., Ltd. is a biopharmaceutical company specializing in the development of innovative, first-in-class drugs for rare and intractable diseases. The company's clinical-stage pipeline focuses on addressing unmet medical needs in ophthalmology and oncology. Key development programs include RGN-259, a therapeutic agent for Dry Eye Disease and Neurotrophic Keratopathy, and OKN-007 for the treatment of Glioblastoma Multiforme. Additionally, the company is advancing a Natural Killer (NK) cell therapy through late-stage clinical trials to provide new therapeutic options for patients.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서), which is a standard regulatory filing in South Korea (often referred to as the 5% rule filing). It details the acquisition of shares, the identity of the reporting entity (G-Tree Holdings), and the purpose of the holding (management participation). This type of document is a specific regulatory disclosure regarding significant ownership changes and does not fit into the other categories like Annual Reports or Earnings Releases. Therefore, it is classified as a Regulatory Filing (RNS).
2021-02-10 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on the Status of Large Shareholdings' (주식등의 대량보유상황보고서), which is a standard regulatory filing in South Korea (often referred to as a 5% report). It details the changes in share ownership by KB Asset Management in the company 'GtreeBNT'. This document type is specifically used to notify the market when a major shareholder crosses certain ownership thresholds or changes their holdings significantly. Based on the provided categories, this fits the 'Major Shareholding Notification' (MRQ) classification.
2021-02-02 Korean
[기재정정]최대주주변경을수반하는주식양수도계약체결
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing (specifically a 'Correction Report' or '정정신고') regarding a 'Change in Largest Shareholder' due to a stock transfer agreement. It details the parties involved, the number of shares, the transaction price, and the timeline for the change. This type of corporate disclosure regarding ownership structure and major shareholding changes falls under the category of 'Major Shareholding Notification' (MRQ) as it pertains to the change in the controlling interest of the company.
2021-02-02 Korean
[기재정정]주요사항보고서(자기주식처분결정)
Transaction in Own Shares Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Korean financial authorities (Financial Services Commission/Korea Exchange). It specifically details a 'Decision on Disposal of Treasury Shares' (자기주식 처분 결정) and includes a correction (정정신고) regarding the identity of the counterparty (the acquirer of the shares). Since this document reports the company's decision to sell its own shares (a share repurchase/disposal event), it falls under the 'Transaction in Own Shares' category.
2021-02-02 Korean
[기재정정]주요사항보고서(전환사채권발행결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Report' (주요사항보고서) filed with the Korea Exchange regarding the 'Decision to Issue Convertible Bonds' (전환사채권 발행결정). It is a formal regulatory filing detailing the terms of the bond issuance, including interest rates, conversion prices, and the identity of the investors. It is not a simple announcement of a report (RPA) but the actual regulatory disclosure of a corporate financing event. Therefore, it is classified as a Regulatory Filing (RNS) as it fits the criteria for miscellaneous regulatory announcements that do not fall into more specific categories like 'Capital/Financing Update' (CAP) in this specific taxonomy, or it serves as the standard regulatory filing format for such corporate actions.
2021-02-02 Korean
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 95% confidence The document is a formal regulatory disclosure regarding a 'Single Sales/Supply Contract' (단일판매ㆍ공급계약체결) between HLB Therapeutics (formerly GtreeBNT) and SK Bioscience. It details the contract value, duration, and nature of the agreement (vaccine distribution management). Since this is a specific material event disclosure regarding a business contract and does not fit into the other specialized categories like M&A, dividends, or financial reports, it falls under the general regulatory filing category.
2021-01-26 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.